Analysts Set Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Price Target at $477.44

Shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) have been assigned an average recommendation of “Moderate Buy” from the twenty-eight analysts that are currently covering the firm, MarketBeat.com reports. One equities research analyst has rated the stock with a sell recommendation, four have issued a hold recommendation and twenty-three have given a buy recommendation to the company. The average 1-year price target among brokerages that have issued ratings on the stock in the last year is $477.4420.

Several research analysts have recently issued reports on the company. Weiss Ratings reissued a “sell (d-)” rating on shares of Alnylam Pharmaceuticals in a research note on Wednesday, October 8th. Barclays increased their target price on shares of Alnylam Pharmaceuticals from $460.00 to $527.00 and gave the company an “overweight” rating in a research report on Friday, October 31st. Evercore ISI boosted their price target on shares of Alnylam Pharmaceuticals from $280.00 to $515.05 and gave the stock an “outperform” rating in a research report on Thursday, September 11th. Wall Street Zen raised shares of Alnylam Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research note on Monday, November 10th. Finally, Truist Financial raised their price objective on shares of Alnylam Pharmaceuticals from $459.00 to $535.00 and gave the company a “buy” rating in a research note on Friday, October 17th.

Alnylam Pharmaceuticals Stock Performance

Shares of ALNY stock opened at $398.70 on Friday. Alnylam Pharmaceuticals has a 12-month low of $205.87 and a 12-month high of $495.55. The company has a debt-to-equity ratio of 4.45, a current ratio of 2.54 and a quick ratio of 2.49. The firm has a market capitalization of $52.67 billion, a price-to-earnings ratio of 1,661.25 and a beta of 0.30. The business has a 50 day simple moving average of $443.63 and a 200 day simple moving average of $412.74.

Insider Activity at Alnylam Pharmaceuticals

In other news, EVP Pushkal Garg sold 3,022 shares of the business’s stock in a transaction on Friday, October 3rd. The stock was sold at an average price of $451.48, for a total value of $1,364,372.56. Following the sale, the executive vice president owned 20,221 shares of the company’s stock, valued at approximately $9,129,377.08. The trade was a 13.00% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, CEO Yvonne Greenstreet sold 15,650 shares of the company’s stock in a transaction on Wednesday, November 12th. The shares were sold at an average price of $453.69, for a total value of $7,100,248.50. Following the completion of the sale, the chief executive officer owned 65,409 shares of the company’s stock, valued at approximately $29,675,409.21. This trade represents a 19.31% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold 60,328 shares of company stock worth $27,288,993 in the last quarter. Company insiders own 1.20% of the company’s stock.

Hedge Funds Weigh In On Alnylam Pharmaceuticals

Hedge funds have recently made changes to their positions in the business. Root Financial Partners LLC acquired a new stake in Alnylam Pharmaceuticals during the third quarter valued at approximately $25,000. SVB Wealth LLC acquired a new position in Alnylam Pharmaceuticals in the first quarter worth approximately $27,000. Salomon & Ludwin LLC bought a new position in shares of Alnylam Pharmaceuticals in the third quarter valued at $27,000. Caitong International Asset Management Co. Ltd acquired a new stake in shares of Alnylam Pharmaceuticals during the 3rd quarter valued at $29,000. Finally, Atlantic Union Bankshares Corp acquired a new stake in shares of Alnylam Pharmaceuticals during the 2nd quarter valued at $30,000. Institutional investors and hedge funds own 92.97% of the company’s stock.

Alnylam Pharmaceuticals Company Profile

Alnylam Pharmaceuticals, Inc (NASDAQ: ALNY) is a biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics. Founded to translate the scientific discovery of RNAi into new medicines, Alnylam applies small interfering RNA (siRNA) technology to silence disease-causing genes. The company develops therapies designed to provide durable disease modification by targeting underlying genetic drivers across a range of rare and more prevalent conditions.

Alnylam has advanced multiple siRNA-based products into commercialization, initially using lipid nanoparticle delivery and more recently employing GalNAc-conjugate chemistry to enable targeted delivery to the liver with subcutaneous dosing.